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Purpose: The circadian rhythm hypothesis of bipolar disorder (BD) suggests a role for mela-
tonin in regulating mood, thus extending the interest toward the melatonergic antidepressant 
agomelatine as well as type I (acute) or II cases of bipolar depression.
Patients and methods: Twenty-eight depressed BD-II patients received open label ago-
melatine (25 mg/bedtime) for 6 consecutive weeks as an adjunct to treatment with lithium or 
valproate, followed by an optional treatment extension of 30 weeks. Measures included the 
Hamilton depression scale, Pittsburgh Sleep Quality Index, the Clinical Global Impression 
Scale–Bipolar Version, Young Mania Rating Scale, and body mass index.
Results: Intent to treat analysis results demonstrated that 18 of the 28 subjects (64%) showed 
medication response after 6 weeks (primary study endpoint), while 24 of the 28 subjects 
(86%) responded by 36 weeks. When examining primary mood stabilizer treatment, 12 of 
the 17 (70.6%) valproate and six of the 11 (54.5%) lithium patients responded by the first 
endpoint. At 36 weeks, 14 valproate treated (82.4%) and 10 lithium treated (90.9%) subjects 
responded. At 36 weeks, there was a slight yet statistically significant (P = 0.001) reduction in 
body mass index and Pittsburgh Sleep Quality Index scores compared to respective baseline 
values, regardless of mood stabilizer/outcome. Treatment related drop-out cases included four 
patients (14.28%) at week 6 two valproate-treated subjects with pseudo-vertigo and drug-induced 
hypomania, respectively, and two lithium-treated subjects with insomnia and mania, respectively. 
Week 36 drop outs were two hypomanic cases, one per group.
Conclusion: Agomelatine 25 mg/day was an effective and well-tolerated adjunct to valproate/
lithium for acute depression in BD-II, suggesting the need for confirmation by future double 
blind, controlled clinical trials.
Keywords: bipolar disorder type-II, acute bipolar depression, agomelatine, adjunctive 
treatment
Introduction
Although the Diagnostic and Statistical Manual for Mental Disorders-Fourth  Edition 
(DSM-IV)1 proposes mania as the hallmark of bipolar disorder (BD), depression 
is the most enduring aspect of the illness,2 requiring intense treatment efforts.3 
 Moreover, the majority of patients with bipolar depression fail to respond adequately 
to  pharmacotherapy.4 For this reason, novel treatments for bipolar depression are 
needed, and despite being controversial due to the uneven results reported in acute 
and long-term follow-up clinical trials, antidepressant medications are commonly 
used for bipolar depression.5 The antidepressant agomelatine is a norepinephrine and 
dopamine disinhibitor drug, acting as a 5-HT2C/2B serotonin receptor antagonist and 
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MT1/MT2 melatonin receptor agonist proven effective in the 
treatment of major depressive disorder (MDD).6–9
In pilot studies of type I BD (BD-I), agomelatine showed 
interesting results.10,11 Yet, to the best of our knowledge, no 
equivalent information has been provided about depression 
in type II BD (BD-II). Because there are important dif-
ferences between BD-I and BD-II in terms of prevalence, 
clinical course, and antidepressant treatment implications, 
the use of agomelatine in the latter condition also warrants 
investigation.
The conceptualization of BD as a disorder of cycling, 
possibly based on disturbances in circadian rhythms, has been 
suggested for centuries. Reports of impaired daily rhythms in 
“emotional disturbances” date back to Hippocrates, Galen, 
Aretaeus of Cappadocia [“…vital tone was subject to typical 
circadian variations”], and later Kraepelin.12 However, it was 
not until after the discovery of melatonin in 1958 that the link 
between the pineal gland and affective disorders, considered 
by 17th century Cartesian theorists, found scientific biologi-
cal support.13 More recently, these observations have been 
articulated into specific hypotheses of circadian rhythms as 
the bases for mood disorders.14,15 Presently, changes in sleep 
are included in the DSM-IV criteria for major depressive 
episodes, including those associated with BD, and sleep 
patterns have been proposed as predictors of manic relapses 
in BD.16 Melatonergic modulation has been shown to be 
relevant in regulating circadian rhythms and sleep patterns, 
both in MDD17,18 and BD,19 and recent evidence suggests an 
association between 5HTR2C gene polymorphisms and BD.20 
Therefore, the circadian rhythm system represents a rational 
target for novel antidepressant medications aiming to address 
these clinical features of BD,21 and due to its unique  receptor 
binding profile, considerable interest has been generated 
around the use of agomelatine.
The principal aim of this open label pilot study was to 
assess the efficacy and safety of adjunctive agomelatine 
pharmacotherapy in the treatment of acute major depression 
in BD-II. As secondary aims, we examined whether there 
were differences in sleep and/or body mass associated with 
agomelatine treatment, and whether any of these outcomes 
were differentially associated with concomitant lithium or 
valproate therapy.
Methods
Participants
Participants aged 18–65 years old were recruited by five 
experienced physicians between November 2010 and May 
2012 through referrals to two main private outpatient practice 
centers in Italy (Genoa and Pisa). Patients were referred by 
general practitioners, psychiatrists, or self-referral. All met 
the DSM-IV criteria for a primary diagnosis of BD-II and 
a current major depressive episode, assessed by the means 
of the Structured Clinical Interview for DSM-IV Axis-I 
Disorders.22 Additional inclusion criteria were a Hamilton 
Depression Rating-Scale 17-item (HAM-D-17)23 baseline 
score $ 18; negative history for adrenal, thyroid, or liver 
diseases; and continuously therapeutic blood levels of 
lithium or valproate for at least 6 months. Exclusion criteria 
included (I) lifetime diagnosis of BD-I, schizophrenia, or 
other psychotic disorders, rapid-cycling or seasonal pat-
terns, history of treatment-resistant depression (defined 
as non-response to two consecutive treatments of at least 
4 weeks each with two different classes of antidepressants), 
Axis-II comorbidity (including mental retardation), and 
alcohol/drug use disorders; (II) severe medical comorbidi-
ties, including organic brain syndrome, clinically significant 
drug interactions (eg, ciprofloxacin), pregnancy, nursing, or 
a woman of childbearing potential who declined the use of 
an adequate contraceptive; (III) concomitant use of another 
mood altering medication in the previous 2 weeks, or 4 weeks 
in the case of fluoxetine (low doses of benzodiazepines [eg, 
lorazepam # 2.5 mg/day] were allowed during the first 
2 weeks); and (IIII) concomitant psychological treatment. 
Written informed consent was obtained from all patients 
prior to enrollment in the study after procedures had been 
fully explained by a senior study coordinator active in 
patients’ recruitment and evaluation. A total of 50 subjects 
were initially screened, and 28 were enrolled in the study 
(F/M = 17/11). Excluded cases included those with sub-
optimal mood stabilizer blood levels (n = 16), those using 
concomitant pharmacotherapies not allowed by the study 
protocol (n = 5), and those with a serious medical illness 
( Gilbert’s syndrome, n = 1). Of the 28 subjects who partici-
pated, 17 (60.7%) were on valproate and 11 (39.3%) were 
taking lithium as their primary mood stabilizer therapy.
Study design
The efficacy of agomelatine as an adjunct to valproate 
(blood levels of 50–125 µg/ml) or lithium (blood levels 
0.6–1.1 mmol/L) in the treatment of an acute BD-II major 
depressive episode was addressed using a 6 week open 
parallel-group design. No blind assessment or placebo con-
trols were adopted, and the patients were regularly monitored 
for safety, with clear instructions to report any unexpected 
adverse events (AEs), including mood changes, to their treat-
ing physician at the earliest possible time.
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Pharmacotherapy
A fixed dose of agomelatine was used during the entire 
study (25 mg at bedtime: 9:00–10:00 pm). Higher doses 
(eg, 50 mg/day) were excluded due to the preliminary nature 
of the study according to safety considerations. During the 
initial period of 6 weeks, a psychiatrist performed clinical 
evaluations every 2 weeks on each subject. Thereafter, the 
patients who continued the trial were evaluated every 6 weeks 
until week 36.
Clinical assessment
Demographic and clinical characteristics were recorded at 
baseline; the HAM-D-17 was the primary measure of mood. 
In all cases, “response” was defined as .50% decrease in 
severity from the baseline HAM-D-17 score. Secondary 
measures were the Severity and Impression modules of the 
Clinical Global Impression Scale–Bipolar Version 24 starting 
at the second week, the Young Mania Rating Scale (YMRS),25 
and the Pittsburgh Sleep Quality Index (PSQI),26 which is a 
self-report instrument used to subjectively measure sleep 
across seven domains: quality, latency, duration, efficiency, 
disturbances, use of medication, and daytime somnolence. 
The scale is designed to assess both the initial quality and 
ongoing comparative measurements of sleep quality, and has 
a reliability Cronbach’s alpha = 0.83.
At every appointment, an assessment, including general 
and psychiatric clinical examinations, was performed. These 
included measurements of blood pressure, heart rate, and 
body mass index (BMI). Routine laboratory tests included 
monitoring of liver functioning (safety, including liver 
enzyme levels, was a secondary endpoint of the study) and 
blood levels of lithium or valproate. All AEs experienced 
by participants were recorded at each study visit, based 
on the clinical judgment of the investigator(s). Due to the 
explorative nature of the study and safety considerations, 
whenever an AE occurred (any degree of severity), this was 
considered grounds for agomelatine discontinuation by the 
investigators. In these cases, subjects were excluded from 
further study.
Statistical analysis
The a priori sample size requirement for the study was 
calculated to be at least 12 in each of the two mood sta-
bilizer groups ($24 patients in total), based on consid-
erations described previously for non-randomized pilot 
studies.27 All statistical analyses were performed using 
IBM® SPSS®Statistics®v.21.0.0 for Microsoft® Windows®8 
Release Preview, Build 8400. Since data followed a normal 
 distribution, they were assessed using the Shapiro-Wilk 
test. Parametric comparative analysis for demographic, 
clinical, and course characteristics of the two groups were 
performed using a Student’s two-tailed t-test for the con-
tinuous variables, and χ2 analysis for categorical variables, 
performing bivariate correlation analysis for selected metrics. 
Significance was set at P , 0.05. Intent to treat analysis was 
performed for efficacy in those patients who took at least one 
capsule of study medication and had at least one valid post-
baseline efficacy evaluation, either on the study medication 
or within 3 days of drug discontinuation.
Results
Patient characteristics
Baseline demographic and clinical characteristics of the study 
subjects are shown in Table 1. There were no significant dif-
ferences in patient characteristics between the lithium and 
valproate treated subjects, although some numerical differences 
may have led to statistical significance with a larger, “non-
pilot,” sample size. All were diagnosed with BD-II, but many 
had secondary psychiatric disorders. Inter-rater reliability on the 
DSM-IV diagnosis indicated substantial agreement among the 
raters (Cohen’s κ = 0.75 [P , 0.0001], 95% CI = 0.65–0.37). 
By adopting a conservative definition of severe depression 
of HAM-D-17 scores . 2828, it was found that five patients 
(17.9%) were severely depressed at study entry (n = 4 [23.5%] 
for valproate and n = 1 [9.1%] for lithium).
Primary outcomes
Using intent to treat analysis, 12 of the 17 valproate treated 
(70.6%) and 6 of the 11(54.5%) lithium treated patients 
demonstrated clinical response to agomelatine augmenta-
tion at the 6 week primary study endpoint. Six valproate and 
one lithium treated patients (25% of the total) responded as 
early as the second week of treatment. Secondary analyses 
conducted at the 6 week assessment are shown in Table 2. 
At the 36 week endpoint, 14 of the 17 (82.4%) valproate 
treated and 10 of the 11 (90.9%) lithium treated subjects had 
a clinical response.
Secondary outcomes
PISQ scores were significantly reduced after 6 weeks com-
pared to baseline (t = 6.738 [27]; P , 0.001), and PISQ scores 
remained lower at week 36 (t = 3.777 [27]; P = 0.001). The 
PISQ reduction was similar in both the valproate and lithium 
groups, and occurred independently of therapeutic response at 
weeks 6 or 36. At week 36, a slight yet  statistically  significant 
(t = 3.777; df = 27; P , 0.001) reduction in BMI score was 
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Table 1 Baseline characteristics of the patients included in the study
Included set 
N = 28
Agomelatine +  
valproate group 
N = 17 (60.7%)
Agomelatine +  
lithium group 
N = 11 (39.3%)
F or χ2  
(df = 2)
P
Sex F/M 17/11 9/8 8/3 0.295 (1) ns
Age in years, 
Mean (SD); (range)
41.29 ± 13.60  
(21–64)
41.94 ± 13.94 
(23–64)
40.27 ± 13.66 
(21–61)
0.174 ns
Age at first diagnosis of BD,  
mean (SD); (range)
26.21 ± 9.79 
(13–59)
25.58 ± 7.68 
(13–42)
27.18 ± 12.76 
(14–59)
1.539 (26) ns
BMI score, mean (SD) 25.33 ± 2.62 25.17 ± 2.85 25.59 ± 2.33 0.610 (26) ns
Positive family history  
for BD-II, N (%)
10 (35.7%) 6 (60%) 4 (40%) 0.003 (1) ns
First episode polarity  
(depressive/hypomanic)
24 (85.7%)/4 (14.3%) 14 (82.4%)/3 (17.6%) 10 (90.9%)/1 (9.1%) 0.399 (1) ns
Reported number of depressive  
episodes (previous 5 years)*
None, N = 16 (57.1%) 
#3, N = 10 (35.7%) 
$4, N = 2 (7.1%)
None, N = 9 (52.9%) 
#3, N = 7 (41.2%) 
$4, N = 1 (5.9%)
None, N = 7 (63.9%) 
#3, N = 3 (27.3%) 
$4, N = 1 (9.1%)
0.591 (2) ns
Duration of current depressive  
episode days (SD); (range)
25.64 ± 18.54; (14–90) 26.18 ± 21.59; (14–90) 24.82 ± 13.47; (14–60) 10.781 (10) ns
HAM-D-17 score (SD); (range) 25.86 ± 3.19; (19–31) 26.53 ± 2.76; (21–31) 24.82 ± 3.65; (19–31) 14.374 (10) ns
YMRS score (SD) 3.46 ± 1.57 3.41 ± 1.73 3.54 ± 1.37 3.544 (6) ns
PSQI score (SD) 11.39 ± 5.31 10.70 ± 4.62 12.45 ± 6.33 12.453 (12) ns
CGI-BP-S (SD) 4.36 ± 1.37 3.94 ± 1.14 5 ± 1.48 5.372 (6) ns
Lifetime axis-I co-morbidity, N (%)
Generalized anxiety disorder 6 (21.4%) 4 (23.5%) 2 (18.2%) 0.113 (1) ns
Obsessive-compulsive disorder 7 (25%) 3 (17.6%) 4 (36.4%) 1.248 (1) ns
Panic disorder 5 (17.9%) 3 (17.6%) 2 (18.2%) 0.001 (1) ns
Specific phobias 8 (26.6%) 4 (23.3%) 4 (36.4%) 0.539 (1) ns
Impulse control disorder 4 (14.3%) 3 (17.6%) 1 (9.1%) 0.399 (1) ns
Anorexia nervosa 1 (3.6%) 1 (5.9%) 0 0.671 (1) ns
Bulimia nervosa 3 (10.7%) 2 (11.8%) 1 (9.1%) 0.050 (1) ns
Binge eating disorder 4 (14.3%) 3 (17.6%) 1 (9.1%) 0.399 (1) ns
Notes: For χ2 and relative, P-values refer to the comparison between the two groups, not versus the whole sample (+valproate vs +lithium). “Age at first diagnosis of BD” 
may differ from age at first medical consultation for major depression or from actual age of onset of BD. *Current MDE excluded.
Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item; 
MDE, major depressive episode; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; YMRS, Young Mania Rating Scales.
Table 2 Comparison of clinical measures at week-6 of the study (last post-baseline value)
Included set 
N = 28
+valproate group  
N = 17 (60.7%)
+lithium group  
N = 11 (39.3%)
F or χ2  
(df = 2)
P
HAM-D-17 mean score (SD) 10.71 (4.52) 10.23 (3.99) 11.45 (5.35) 11.58 (12) ns
YMRS mean score (SD) 7.89 (5.14) 6.94 (3.38) 9.36 (7.01) 10.531 (8) ns
BMI score, mean (SD) 25.27 (3.26) 25.59 (3.21) 24.77 (3.43) 16.610 (15) ns
CGI-BP-S mean (SD) 4.18 (1.28) 3.82 (1.13) 4.73 (1.35) 4.742 (5) ns
CGI-BP-I mean (SD) 2.78 (1.64) 2.88 (1.87) 2.64 (1.29) 2.306 (6) ns
PSQI mean (SD) 4.61 (1.42) 4.88 (1.41) 4.18 (1.40) 3.835 (5) ns
Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item; 
PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation; YMRS, Young Mania Rating Scales.
observed in the intent to treat population (24.32 ± 2.26 vs 
baseline 25.33 ± 2.62) regardless of the primary mood sta-
bilizer treatment. Specifically, mean BMI scores at week 
36 were 24.73 ± 2.12 among valproate treated subjects and 
23.68 ± 2.43 among lithium treated subjects. Also, at week 
36, there was a trend toward a negative correlation between 
BMI and HAM-D-17 score (r = –0.16; P = ns). There was 
no correlation between BMI and PISQ (r = –0.06; P = ns). 
Additional information about the trend of specific clinical 
variables within the trial is reported in Figure 1.
Adverse events
Four patients (14.28% of the total) dropped out due to a 
treatment-related AE by week 6. In the valproate group, these 
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Figure 1 Trend of different rating and clinical parameters at weeks 6 and 36 between the two groups.
Note: While the figure fails to show any substantial differences between groups, this highlights the fact that the effect of agomelatine add-on therapy was substantially 
maintained within week 6 and week 36, independent of the ongoing mood stabilizer treatment.
Abbreviations: BMI, body mass index; CGI-BP-I/S, Clinical Global Impression/Severity scales for Bipolar Disorder; HAM-D-17, Hamilton Depression Rating-Scale 17-item; 
PSQI, Pittsburgh Sleep Quality Index; YMRS, Young Mania Rating Scales.
included a single case each of pseudo-vertigo and hypomania; 
in the lithium group, these included a single case of insomnia 
and mania (YMRS = 30).
Two additional cases left the study at week 36 due to 
hypomania. These included one each in both the valproate 
(YMRS = 17) and lithium (YMRS = 16) treated groups. 
Notably, whenever an AE occurred, this was judged as severe 
and considered responsible for drop out.
Discussion
Overview and limits of the study
Our results suggest that adjunctive agomelatine may be useful 
in the treatment of acute depression in BD-II. During both 
the short- and longer-term periods of the trial, agomelatine 
treatment was associated with improvements in depression 
and sleep quality and was well tolerated.
Nonetheless, the study was limited by several important 
factors that warrant discussion, especially in light of the 
potential “publication and outcome reporting” biases that 
have arisen regarding randomized controlled studies involv-
ing agomelatine in the treatment of MDD.29
Additionally, the pharmacodynamics of agomelatine 
need to be better characterized in human samples. In fact, 
by inhibiting 5-HT2C receptors, agomelatine secondarily 
increases norepinephrine and dopamine in the frontal cortex 
of the brain of animals, while the drug binding and coupling 
profiles of h5-HT2B and h5-HT2C receptors are similar, and 
agomelatine also blocked 5-HT-induced [3H]PI depletion 
at h5-HT2B sites.30 However, 5-HT2B receptors are poorly 
represented in the central nervous system, wherein their 
functional significance remains substantially obscure.31
Due to safety reasons and the preliminary nature of the 
study, raters also participated in the clinical management 
and were therefore not blind to treatment assignments 
(“measurement bias”). Moreover, because agomelatine is 
not yet supplied for free by the National Health System in 
Italy (unlike many medications), this naturalistic study may 
suffer from an additional selection bias, favoring recruitment 
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of patients who were more financially stable and/or motivated 
for treatment, potentially influencing both the drop-out rate 
and medication adherence (“under/over-reporting bias”), 
especially in the optional 30 week extension period. Despite 
these limitations, our results should stimulate further inves-
tigation of agomelatine and BD-II.
On the other hand, since the ultimate goal of treatment in 
“acute” bipolar depression should be establishing long-term 
mood stability,32 the lack of additional follow up, ideally 
beyond 52 weeks,11 needs to be noted, although very few 
pilot studies would indeed follow this criterion. However, it 
is worthy of notice that during both the acute and extension 
periods of the trial, adjunctive agomelatine treatment was 
associated with improvement in depression, with favorable 
safety and tolerability profiles, including sensitive issues such 
as liver (there was no clinically relevant enzyme modification 
within the trial) and sexual function,29,33,34 although these lat-
ter outcomes were not assessed by ad hoc instruments, and 
improvement of subjective sleep quality – when initially 
impaired – was not assessed by actigraphic techniques or 
by other objective neurophysiological measurements due to 
the very preliminary nature of the study, whereas lithium or 
valproate may have contributed both to the antidepressant 
response and, possibly, to modulation of MT1/MT2 melaton-
ergic receptors as already documented in animal models.35,36 
Finally, the fact that the mean duration of depression was 
less than 4 weeks (with a lower range of 2 weeks) cannot 
exclude the chance of spontaneous improvement due to 
the natural course of depression for those subjects judged 
as “responders”; equally, the eventual predictive role of 
anxious co-morbidity (when present) could not be evinced 
at this time due to the small sample size and methodological 
limits of this preliminary study, although agomelatine has 
been anecdotally reported to have a promising modulating 
role in anxious disorders.37–43
Agomelatine, sleep, and depression
The effects of agomelatine on sleep have already been 
documented by different studies on MDD samples. Among 
others, a comparative study with venlafaxine highlighted a 
statistically significant improvement of sleep with agomela-
tine,44 a faster improvement of the “circadian rest-activity 
cycle” compared to sertraline,45 and a better rapid eye move-
ment profile – but not short wave sleep profile, possibly due 
to 5-HT2C antagonism in comparison to escitalopram,46 
although the degree to which 5-HT2C receptor antagonism 
explains or contributes to the antidepressant or sleep effect 
of agomelatine has been questioned in humans.47
Sleep disturbances are a core aspect of BD and may 
often predict subsequent manic switch.48 In our study and 
in others, agomelatine led to sustained subjective improve-
ments in sleep quality in association with either lithium or 
valproate, beginning as early as 2 weeks into treatment. 
The concomitant use of benzodiazepines during the first 
2 weeks may have influenced these results, but is unlikely 
to account for the effect since only a minority patients used 
these medications (n = 3/28; 10.7%), and no patients used 
them beyond the second week. Improved sleep quality may 
have important clinical implications for BD-II, but may 
not necessarily improve mood.49 While insomnia has been 
reported as a major predictor of depression,50 abnormalities 
in sleep architecture, including disturbances of sleep consoli-
dation, slow-wave sleep, and rapid eye movement sleep are 
common during antidepressant treatments, suggesting sleep 
quality and mood state are dissociable.51,52 Paradoxically, 
four patients (14.3%) experienced insomnia while taking 
agomelatine. This problem was effectively managed after 
exclusion from the study by switching the time of agomela-
tine administration from bedtime to early morning, without 
any subsequent manic switch. While not described in previous 
trials, this unexpected insomnia may be related to circadian 
phase abnormalities associated with depression. In seasonal 
depression, most patients are thought to be phase delayed and 
respond to the phase advancing effects of evening melatonin. 
In contrast, ∼30% may be phase advanced.53 In these latter 
cases, evening melatonin receptor stimulation may lead to a 
worsening of the circadian abnormality by further advancing 
phase, perhaps disrupting sleep onset and causing nighttime 
insomnia. If these findings generalize to bipolar depression, 
among the minority of subjects with advanced phase, morn-
ing agomelatine would correct the abnormality by delaying 
phase to a more optimal time.
Adverse events and manic switch
While relatively few in number, our study did have AEs to 
report, including four mood switches to (hypo-) mania. The 
rate of manic/hypomanic switch was lower than expected 
based on previous clinical experience with other antidepres-
sants added to mood stabilizers in the treatment of acute 
depression in BD-II, yet was still remarkable compared to 
other established antidepressants.54 Nonetheless, the profile 
of agomelatine with regard to manic switching is consistent 
with preliminary reports from BD-I;10 since the safety of 
antidepressants in bipolar depression is of great interest in 
modern clinical psychiatry, further research on this issue is 
needed for agomelatine to reliably compare corresponding 
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data coming from controlled trials on other antidepressants, 
ideally looking at long-term treatment compliance and 
stability.55
The occurrence of “pseudo-vertigo” (dizziness not 
involving a sense of rotation, which is common in the 
course of panic disorders, hyperventilation, and orthostatic 
 hypotension) in three patients was another unexpected AE 
that was encountered. Of note, a previous case report sug-
gested an interaction between agomelatine and the melaton-
ergic neurons of the cerebellum in a minority of sensitive 
individuals.38 Larger studies are required to determine the 
rate of AE associated with this problem.
Implications for the circadian rhythm 
hypothesis of BD
With the associated disruptions in sleep and daily activity 
cycles, circadian rhythm abnormalities have been proposed 
to play a role in the etiology of mood disorders, including 
BD. Both lithium and valproate, the mood stabilizers used in 
our study, have effects on circadian rhythms,56–58 and genetic 
variants in clock genes have been associated with lithium 
response.59 BD patients have been reported to be particularly 
sensitive to environmental events,60,61 a feature that has also 
been associated with circadian instability,62 suggesting that 
biological rhythms play a critical role in the emotional dys-
regulation at the center of BD.19,63,64 Central to the circadian 
effects on mood is the availability of light.  Differential 
outcomes in antidepressant response are associated with 
specific changes in retinal physiology, suggesting that proper 
timing of light input into the central nervous system may be 
an important aspect of antidepressant response.65
In this context, it is interesting to consider the implica-
tions of our agomelatine findings with respect to the circadian 
clock hypothesis of mood disorders. We found changes in 
sleep quality and BMI, the latter presumably reflecting 
differences in dietary intake and/or motor activity. It is 
interesting to note that regardless of the use of drugs that 
affect the clock in distinct ways (lithium and valproate), the 
effects of agomelatine on rhythmically influenced behaviors 
did not differ by the concomitant mood stabilizer. Of inter-
est, previous reports have described melatonergic neurons 
outside the central nervous system, including those in the 
gastrointestinal tract, that are influenced both by light/dark 
cycles and environmental stressors.66–69 Collectively, these 
findings lend support to the supposed interaction between 
melatonergic regulation on mood and the “gut-clock”.70 
If further evidence supports the hypothesis that agomela-
tine functions as core “rhythm regulator,”71 it could play 
a therapeutic role for those BD patients with prominent 
imbalances in eating rhythms, and may extend the concept 
of rhythm disturbances in mood disorder to include feeding 
behavior and metabolic activity in addition to sleep/wake 
behavior.72–75 This could be in marked contrast to standard 
antidepressants, with their propensity toward causing weight 
gain via serotonergic stimulation of 5-HT2A receptors 
rather than selective antagonism of 5-HT2C.9,51,76,77 It will be 
of interest in the future to determine whether agomelatine 
affects excessive or atypical eating behaviors in the context 
of depression, especially in the view that animal studies have 
reported that 5-HT2B agonists concur with hyperphagia and 
reduce grooming in rodents,78 whereas stimulation of 5-HT2B 
sites exerts actions in animal peripheral tissues, especially in 
development. However, there is no evidence for a functional 
effect of antagonists at these sites79 and agomelatine is yet to 
be characterized in this regard in human samples.
Concluding remarks
Adjunctive agomelatine treatment with lithium or valproate 
in the acute phase of BD-II major depression led to substan-
tial positive results in our preliminary open label trial. Large 
double-blind randomized controlled studies are warranted 
and will be essential to providing more definitive evidence of 
the efficacy, safety, and optimal dose-range profile compared 
to MDD usage.80
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